One-Month Dual Antiplatelet Therapy followed by Potent P2Y12 Inhibitor Monotherapy After Orsiro Mission® Stent Implantation in Patients with Acute Coronary Syndrome: DAPT-SIRO TRIA

Chonnam National University Hospital0 个研究点目标入组 2,000 人开始时间: 待定最近更新: 2022年1月11日

适应症

试验速览

暂无简介。

•1) Adults 19 years of age or older
•2) Acute coronary patients who had successful percutaneous coronary intervention (PCI) with Orsiro Mission® stent
•3) Subjects who agree to the research protocol and clinical follow-up plan, decide voluntarily to participate in this clinical study, and agree in writing to the subject consent form

•1) Subjects with known hypersensitivity or contraindication to the following drugs or substances: heparin, aspirin, prasugrel, ticagrelor, sirolimus, contrast agent
•2) If you are taking anticoagulants: warfarin, apixaban, rivaroxaban, dabigatran, edoxaban
•3) In case of previous myocardial infarction or coronary artery revascularization (percutaneous coronary intervention or coronary artery bypass surgery)
•4) Subjects with a transient ischemic attack (TIA) or stroke
•5) Subjects of fertile age who are planning to become pregnant or cannot rule out the possibility of pregnancy during the study period
•6) Subjects whose remaining life expectancy is less than 1 year
•7) Subjects who visited the hospital due to cardiac arrest or psychogenic shock and whose survival is predicted to be low by medical judgment
•8) Complex lesions – unprotected left main lesions, chronic obstructive lesions, severely calcified or tortuous lesions
•9) You are participating in another randomized controlled study, or you are participating in an observational study that may affect the study.
•10) In case the researcher judges that it is not suitable for this clinical study or may increase the risk related to research participation
•11) Patients with severe renal and hepatic dysfunction including hemodialysis patients and cirrhosis patients

发起方